B
HARP

Bailard’s Harpoon Therapeutics, Inc. Common Stock HARP Stock Holding History

Bailard’s Portfolio HARP Stock Details HARP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-6,320
Closed -$47K – 805
2023
Q1 		$47K Buy
+6,320
New +$53.1K ﹤0.01% 696
2021
Q3 		– Sell
-11,888
Closed -$1.65M – 779
2021
Q2 		$1.65M Sell
11,888
-1,190
-9% -$227K 0.06% 223
2021
Q1 		$2.74M Sell
13,078
-718
-5% -$144K 0.1% 160
2020
Q4 		$2.29M Buy
13,796
+896
+7% +$138K 0.1% 146
2020
Q3 		$2.19M Buy
12,900
+2,550
+25% +$368K 0.11% 144
2020
Q2 		$1.72M Sell
10,350
-1,200
-10% -$187K 0.1% 152
2020
Q1 		$1.34M Buy
+11,550
New +$1.62M 0.1% 151

Other funds holding HARP

MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return

Bailard's HARP Position: Q2 2023 in Review

Bailard sold out of Harpoon Therapeutics, Inc. Common Stock (HARP) in Q2 2023, closing a stake of 6,320 shares — an estimated $47K sold.

Bailard first reported a position in HARP in Q1 2020 and held it in 7 quarters. The position peaked at $2.74M in Q1 2021. 44 funds tracked by Wall St. Rank hold HARP as of Q2 2023.

  • Bailard reported no remaining Harpoon Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Bailard sold 6,320 Harpoon Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $47K.
  • Bailard first reported a position in Harpoon Therapeutics, Inc. Common Stock in Q1 2020 and held it in 7 quarters.
  • Bailard's Harpoon Therapeutics, Inc. Common Stock position peaked at $2.74M in Q1 2021.
  • 44 funds tracked by Wall St. Rank held Harpoon Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Bailard's 13F filing for Q2 2023, filed 20 Jul 2023.